Industry Research Reports and Market Analysis at MindBranch.com

Allergy Drug Pipeline and R&D 2009

Published By: Fuji-Keizai USA, Inc.
June 2009
R98-213
Hard Copy Mail Delivery   $995.00 (Subject to Shipping Charges)
Corporate License Fulfilled By Publisher   $2,995.00
Department License Fulfilled By Publisher   $1,495.00
Description

This report describes current global research initiatives in the field of allergies. It focuses on the most common allergies, which affect more than 300 million persons worldwide: seasonal and perennial allergic rhinitis and food allergies.

Sales estimates from 2008 to 2013 are provided for the leading prescription allergy drugs and vaccines, as well as over-the-counter (OTC) allergy medicines in the U.S., European Union, Japan and rest of world area (defined as South America and the Caribbean, Middle East, Africa, and Asia except Japan). Forecasts include an analysis of the market forces affecting sales in each region, as well as a discussion of patent expirations of leading medications and the effects of generic competition on existing allergy drug sales.

Allergy medications and vaccines under development are discussed, with a comprehensive analysis of technology, stage of development and commercialization potential. This includes new molecular entities and indication expansions of medicines currently approved for other uses. For leading allergy drug candidates, sales estimates from 2009 to 2013 are provided.

Profiles of the 12 leading allergy drug developers offer details of these companies’ capabilities, particularly focusing on R&D strength, pipeline products, strategic alliances and partnerships, and the effects of any recent merger or acquisition activity. A directory of more than five dozen leading players worldwide allows readers to access companies’ own web sites for further review.

Information for this report was gathered from a wide variety of published sources; interviews with company representatives were then conducted to assess trends, and form the basis of the forecasting and competitive analysis.

This report is designed for business development and other senior executives, marketers, R&D managers, investors, VCs, consultants, entrepreneurs and others who require an in-depth understanding of the current status of the allergy therapeutics market and potential new products. More than 50 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like.
Table of Contents
Executive Summary
1. Overview of the Global Allergy Medications Market
1.1 Allergies as a Medical Condition
1.1.1 Types of Allergies
1.1.2 Signs and Symptoms
1.1.3 Physiological Response
Table 1-1. Gell & Coombs Classification of Allergic Reactions
1.1.4 Prevalence
Table 1-2. Global Prevalence of Allergies
1.2 Medical Treatment of Allergies
1.2.1 Prescription Medications: Current Usage & Unmet Needs
Table 1-3. Leading Prescription Allergy Medications
1.2.1.1 U.S.
Table 1-4. U.S. DTC Advertising for Leading Rx and OTC Allergy Medications 2008
1.2.1.2 Europe
1.2.1.3 Japan
1.2.1.4 ROW
1.2.2 Non-Prescription Products: Current Usage & Unmet Needs
Table 1-5. Leading OTC Allergy Medications
1.2.2.1 U.S.
1.2.2.2 Europe
1.2.2.3 Japan
1.2.2.4 ROW
2 Global Allergy Medications Market Forecast 2008 - 2013
2.1 Rx Allergy Medications Market
2.1.1 Rx Allergy Drug Market Forecast by Product
2.1.1.1 Growth Drivers
Table 2-1. Rx Allergy Drug Market Forecast 2008 - 2013 by Product in $Million
2.1.1.2 Market Restraints
Table 2-2. U.S. Patent Expirations of Leading Prescription Allergy Drugs
2.1.2 Rx Allergy Drug Market Forecast by Region
Table 2-3. Rx Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
2.1.3 Rx Allergy Drug Market Forecast by Product Class
Table 2-4. Rx Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
Table 2-5. Rx Allergy Drug Market Product Segments Share, 2008 vs. 2013
Figure 2-1. Rx Allergy Drug Market Product Segments Share, 2008
Figure 2-2. Rx Allergy Drug Market Product Segments Share, 2013
2.2 OTC Allergy Drug Market
2.2.1 OTC Allergy Drug Market Forecast by Product
Table 2-6. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product in $Million
2.2.2 Growth Drivers
2.2.3 Market Restraints
2.2.4 OTC Allergy Drug Market Forecast by Region
Table 2-7. OTC Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
2.2.5 OTC Allergy Drug Market Forecast by Product Class
Table 2-8. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
2.3 Rx & OTC Allergy Drug Market
2.3.1 Rx & OTC Allergy Drug Market Forecast by Leading Manufacturers
Table 2-9. RX & OTC Allergy Drug* Sales of Leading Manufacturers, 2008 - 2013 in $Million
2.3.2 Rx & OTC Allergy Drug Market Share of Leading Drug Manufacturers
Table 2-10. Rx & OTC Market Shares of Leading Allergy Drug Manufacturers, 2008 vs. 2013
Figure 2-3. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2008
Figure 2-4. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2013
3. Allergy Drug Development: New Molecular Entities
Table 3-1. Key Characteristics of NMEs, Generics and Indication Expansions
3.1 All Allergy Drug Developers Position
3.1.1 Challenges in Allergy Drug Development
Table 3-2. All Allergy Drug Developers Product Position Overview
3.2 Key Products Under Development
Figure 3-1. Allergy Compounds Tested by Phase of Development
3.2.1 Antihistamines
3.2.1.1 Physiology and Mechanism of Action
3.2.1.2 Leading Antihistamine Allergy Drug Candidates
Table 3-3. Antihistamine Developers Product Position
3.2.2 Corticosteroids
3.2.2.1 Physiology and Mechanism of Action
3.2.2.2 Leading Corticosteroid Allergy Drug Candidates
Table 3-4. Corticosteroid Developers Product Position
3.2.3 Mast Cell Inhibitors
3.2.3.1 Physiology and Mechanism of Action
Figure 3-2. The Role of Mast Cells in Allergy Response
3.2.3.2 Leading Mast Cell Inhibitor Allergy Drug Candidates
Table 3-5. Mast Cell Inhibitors Developers Product Position
3.2.4 Allergy Immunotherapy
3.2.4.1 Physiology and Mechanism of Action
3.2.4.2 Leading Immunotherapy Allergy Drug Candidates
Table 3-6. Immunotherapy Developers Product Position
3.2.5 Vaccines
3.2.5.1 Physiology and Mechanism of Action
Figure 3-3. Production of TH2 Cytokines
3.2.5.2 Leading Allergy Vaccine Candidates
Table 3-7. Vaccine Developers Product Position
3.2.6 Other Types of Allergy Drugs
3.2.6.1 Physiology and Mechanism of Action
3.2.6.2 Other Leading Allergy Candidates
Table 3-8. Other Allergy Drug Developers Product Position
3.3 Global Market Forecast for New Allergy Drugs, 2008 - 2013
3.3.1 New Allergy Drug Market Forecast: Total and Segment Market
Table 3-9. Sales of New Allergy Drugs by Segment, 2008 - 2013
Figure 3-4. Market Shares of New Allergy Drugs by Segment, 2013
3.3.2 Growth Drivers
3.3.2.1 The Importance of Patents
3.3.3 Market Restraints
4. Allergy Drug Development: Indication Expansion
4.1 Indication Expansion for New Usage
Table 4-1. Selected Recent Allergy Drug Indication Expansions, U.S.
4.1.1 The Economic Benefits of Indication Expansion
Table 4-2. U.S. R&D Expenditure for New Medicines by the Pharma-Industry
4.1.2 Challenges in Allergy Drug Indication Expansion
Figure 4-1. Cost and Time Savings of Indication Expansions
4.2 Key Products Under Development
4.2.1 Database of Allergy Indication Expansion Initiatives by Company
Table 4-3. Selected Allergy Drug Indication Expansion Trials
4.2.2 Leading Areas of R&D Activity
4.2.2.1 Clarinex
4.2.2.2 Nasonex
4.2.2.3 Patanase
4.2.2.4 Singulair
4.2.2.5 Veramyst
4.2.2.6 Xolair
4.2.2.7 Xyzal
4.3 Global Market Forecast for Allergy Drug Indication Expansions
Table 4-4. Sales of Allergy Drug Indication Expansions, 2008 - 2013 in $ Million
Table 4-5. Product Market Share of Allergy Drug Indication Expansions, 2009 vs. 2013
Figure 4-2. Product Market Share of Allergy Drug Indication Expansions, 2009
Figure 4-3. Product Market Share of Allergy Drug Indication Expansions, 2013
4.3.1 Growth Drivers
4.3.2 Market Restraints
5. Allergy Drug Development: Basic Research
5.1 Basic Research Group & Activity
Table 5-1. Leading Organizations & Details for Basic Allergy Research
5.1.1 Challenges in Basic Allergy Research
Figure 5-1. National Institutes of Health Research Budget by Disease Area, Fiscal 2008
5.2 Key Areas of Investigation
Table 5-2. Recent Basic Research in the Field of Allergies
5.3 Unanswered Questions
6. Strategic Alliances for Allergy Drug Development
6.1 Types of Strategic Alliances
Figure 6-1. Comparison of Selected Deal Types
6.2 Current Strategic Alliances for Allergy Drug Development
Table 6-1. Ongoing Strategic Alliances for Allergy Drug Development
7. Activities of the Leading Allergy Drug Developers
Common Research Item:
1) Table: Product Profile:
2) R&D Strength and Capabilities
3) Marketed Allergy Drugs
4) Allergy Drug Pipeline
5) Table: Profile
7.1 Alcon Research
7.2 Allergy Therapeutics
7.3 AstraZeneca
7.4 GlaxoSmithKline
7.5 Johnson & Johnson
7.6 Meda AB
7.7 Merck
7.8 Novartis
7.9 Sanofi-Aventis
7.10 Schering-Plough
7.11 Sepracor
7.12 UCB Pharma
8. Total Allergy Drug Market: Forecasts & Directions
Table 8-1. Total Allergy Drug Sales by Segment, 2008 - 2013 in $Million
Figure 8-1. Total Allergy Drug Sales Growth by Segment, 2008 - 2013
Figure 8-2. Allergy Drug Market Share by Segment, 2008
Figure 8-3. Allergy Drug Market Share by Segment, 2013
9. Other Top Companies with Allergy Projects
Table 9-1. Other Top Companies with Late Stage Allergy Projects
Table 9-2. Other Top Companies with Early Stage Allergy Projects
10. Database of Allergy Drug Developers
Order Form
       * Please reference product number R98-213 when ordering or inquiring.
PUBLICATION:   Allergy Drug Pipeline and R&D 2009
QTY. FORMAT PRICE TOTAL
  Hard Copy Mail Delivery (Subject to Shipping Charges)$995.00   
  Corporate License Fulfilled By Publisher$2,995.00   
  Department License Fulfilled By Publisher$1,495.00   
  SUBTOTAL   
SHIPPING CHARGES
 (U.S. $25, Canada $35, Int'l $65) 		 
TOTAL  

CONTACT INFORMATION
PAYMENT INFORMATION
Name ____________________________________________ MasterCard VISA AmEx Discover

__________________________________
Account number                 Exp. date

__________________________________
Signature

__________________________________
Email

Please invoice
      (shipment on receipt of payment)
Payment enclosed
*CHECKS / WIRE TRANSFERS:
Checks must be paid in U.S. funds.
Please call for details.
Company ____________________________________________
Job Title ____________________________________________
Address ____________________________________________
City ____________________________________________
Company ____________________________________________
State ______________________________   Zip__________
Country ____________________________________________
Phone ____________________________________________
MindBranch, Inc.,     131 Ashland St., Suite 200 North Adams, MA  01247       tel: 800-774-4410     fax: +1-413-664-9791     www.mindbranch.com